{"ATC Code":"R - Respiratory system","Abbreviation":"","Aliases":["dyphylline","Diphylline","7-(2,3-Dihydroxypropyl)theophylline","Diprophyllin","Glyphylline","Protheophylline","Aristophyllin","Corphyllin","Diprofillin","Diprofilline"],"Biological Half-Life":"2 hours (range 1.8 - 2.1 hours)","CAS":"479-18-5","ChEBI":"CHEBI:4728","ChEMBL":"CHEMBL1752","ChemicalClasses":["xanthine"],"Chirality":"racemic","Classes":null,"Color/Form":"CRYSTALS FROM ALCOHOL","Drug Classes":"Breast Feeding; Lactation; Milk, Human; Anti-Asthmatic Agents; Bronchodilator Agents","Drug Indication":"For relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema.","Drug Warnings":"IT IS NOT RECOMMENDED FOR USE IN CORONARY DISEASE OR ANGINA PECTORIS UNTIL IT CAN BE SHOWN THAT INCR CORONARY BLOOD FLOW PRECEDES RATHER THAN FOLLOWS MYOCARDIAL STIMULATION.","DrugClasses":[],"EINECS":"207-526-1","EliminationHalfLife":"","Erowid Experience Reports":[],"European Community (EC) Number":"207-526-1","HMDB ID":"HMDB0014789","HeavyAtomCount":18,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Anti-Asthmatic Agents; Bronchodilator Agents","IUPACName":"7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione","Impurities":["proxyphylline","theophyllidine","etofylline","theophylline"],"InChI":"InChI=1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3","InChIKey":"KSCFJBIXMNOVSH-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)","Melting Point":"155-157","MolecularFormula":"C\u003csub\u003e10\u003c/sub\u003eH\u003csub\u003e14\u003c/sub\u003eN\u003csub\u003e4\u003c/sub\u003eO\u003csub\u003e4\u003c/sub\u003e","MolecularWeight":"254.24 g/mol","Opticalactivity":"( + / - )","Pharmacodynamics":"Dyphylline, a xanthine derivative, is a bronchodilator used for relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema. Dyphylline is a xanthine derivative with pharmacologic actions similar to theophylline and other members of this class of drugs. Its primary action is that of bronchodilation, but it also exhibits peripheral vasodilatory and other smooth muscle relaxant activity to a lesser degree.","Physical Description":"Solid","PrevSalts":[],"PubChemId":3182,"Record Description":["Dyphylline is an oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs. It has a role as a bronchodilator agent, a vasodilator agent, an EC 3.1.4.* (phosphoric diester hydrolase) inhibitor and a muscle relaxant. It is an oxopurine and a member of propane-1,2-diols.","Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis.","Dyphylline has been reported in Haplophyllum patavinum and Haplophyllum tuberculatum with data available.","Dyphylline is a xanthine derivative. Dyphilline exerts bronchodilator effects and to a lesser extent vasodilator and diuretic properties. Dyphilline probably acts as a competitive inhibitor of phosphodiesterase which leads to an increase in intracellular cAMP. This results in relaxation of bronchial smooth muscle and other smooth muscles. Dyphylline may also antagonize adenosine receptors. Dyphylline is used in the treatment of acute bronchial asthma, chronic bronchitis and emphysema.","DYPHYLLINE is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951 and is indicated for airway obstruction.","A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.","Dyphylline is an oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs. It has a role as a bronchodilator agent, a vasodilator agent, an EC 3.1.4.* (phosphoric diester hydrolase) inhibitor and a muscle relaxant. It is an oxopurine and a member of propane-1,2-diols.","LiverTox|Respiratory|Bronchodilation|Xanthine"],"RefCount":3,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Diprophylline","Name":"Diprophylline","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q1073333","Name":"Diprophylline","Sub":false},{"Link":"https://www.wikidata.org/wiki/Q27126923","Name":"(+)-Diprophylline","Sub":true}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00651","Name":"Diprophylline","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3182","Name":"Diprophylline","Sub":false},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/688352","Name":"(+)-Diprophylline","Sub":true}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1752","Name":"Diprophylline","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4728","Name":"Diprophylline","Sub":false},{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:59847","Name":"(+)-Diprophylline","Sub":true}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=479-18-5","Name":"Diprophylline","Sub":false},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=72376-77-3","Name":"(+)-Diprophylline","Sub":true}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014789","Name":"Diprophylline","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07819","Name":"Diprophylline","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/263T0E9RR9","Name":"Diprophylline","Sub":false},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/S3D1493BSS","Name":"(+)-Diprophylline","Sub":true}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID6022975","Name":"Diprophylline","Sub":false},{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID301333229","Name":"(+)-Diprophylline","Sub":true}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 3182, Diprophylline. Accessed June 26, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/3182\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/3182\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Diprophylline. UNII: 263T0E9RR9. Global Substance Registration System. Accessed June 26, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/263T0E9RR9\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/263T0E9RR9\u003c/a\u003e"],"SMILES":"CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O","Scheduling":[{"gov":"United States","ref":[],"schedule":"prescription only substance"}],"Solubility":"\u003e38.1 [ug/mL] (The mean of the results at pH 7.4)","Stability/Shelf Life":"IS STABLE IN GASTRIC JUICE","StereoisomerRacemic":"(RS)-Diprophylline","Stereoisomers":["(+)-Diprophylline"],"StereoisomersUNII":["S3D1493BSS"],"StoreUNII":["263T0E9RR9"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="82.042mm" version="1.2" viewBox="0 0 103.363 82.042" width="103.363mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="83.0" stroke="none" width="104.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="29.224" x2="29.224" y1="81.132" y2="69.742"/>
                  
            <line class="bond" id="mol1bnd2" x1="32.378" x2="42.432" y1="64.073" y2="58.272"/>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="42.432" x2="42.432" y1="58.272" y2="43.032"/>
                        
                <line x1="39.994" x2="39.994" y1="56.864" y2="44.44"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd4" x1="42.432" x2="29.224" y1="43.032" y2="35.412"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="28.005" x2="28.005" y1="36.115" y2="24.093"/>
                        
                <line x1="30.443" x2="30.443" y1="36.115" y2="24.093"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="28.005" x2="28.005" y1="24.093" y2="30.104"/>
                <line class="hi" stroke="#FF0D0D" x1="30.443" x2="30.443" y1="24.093" y2="30.104"/>
            </g>
                  
            <line class="bond" id="mol1bnd6" x1="29.224" x2="19.17" y1="35.412" y2="41.213"/>
                  
            <line class="bond" id="mol1bnd7" x1="16.016" x2="16.016" y1="46.882" y2="58.272"/>
                  
            <line class="bond" id="mol1bnd8" x1="26.071" x2="16.016" y1="64.073" y2="58.272"/>
                  
            <g class="bond" id="mol1bnd9">
                        
                <line x1="17.236" x2="6.707" y1="58.975" y2="65.057"/>
                        
                <line x1="16.016" x2="5.487" y1="56.864" y2="62.945"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="6.707000000000001" x2="11.9715" y1="65.057" y2="62.016000000000005"/>
                <line class="hi" stroke="#FF0D0D" x1="5.487" x2="10.7515" y1="62.945" y2="59.9045"/>
            </g>
                  
            <line class="bond" id="mol1bnd10" x1="12.863" x2="2.819" y1="41.211" y2="35.41"/>
                  
            <line class="bond" id="mol1bnd11" x1="42.432" x2="53.687" y1="43.032" y2="39.411"/>
                  
            <line class="bond" id="mol1bnd12" x1="59.566" x2="65.902" y1="41.94" y2="50.652"/>
                  
            <g class="bond" id="mol1bnd13">
                        
                <line x1="59.566" x2="65.902" y1="59.363" y2="50.652"/>
                        
                <line x1="57.594" x2="62.887" y1="57.929" y2="50.652"/>
                      
                <line class="hi" stroke="#3050F8" x1="59.566" x2="62.734" y1="59.363" y2="55.0075"/>
                <line class="hi" stroke="#3050F8" x1="57.594" x2="60.2405" y1="57.929" y2="54.2905"/>
            </g>
                  
            <line class="bond" id="mol1bnd14" x1="42.432" x2="53.687" y1="58.272" y2="61.892"/>
                  
            <line class="bond" id="mol1bnd15" x1="58.195" x2="61.688" y1="34.577" y2="23.87"/>
                  
            <line class="bond" id="mol1bnd16" x1="61.688" x2="76.599" y1="23.87" y2="20.72"/>
                  
            <line class="bond" id="mol1bnd17" x1="76.599" x2="81.326" y1="20.72" y2="6.231"/>
                  
            <line class="bond" id="mol1bnd18" x1="81.326" x2="92.608" y1="6.231" y2="3.848"/>
                  
            <line class="bond" id="mol1bnd19" x1="76.599" x2="84.125" y1="20.72" y2="29.099"/>
                  
            <path class="atom" d="M31.165 68.342h-.72l-2.62 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.483v-2.768h.578v4.9z" fill="#3050F8" id="mol1atm2" stroke="none"/>
                  
            <path class="atom" d="M31.483 20.169q.0 .756 -.256 1.327q-.256 .566 -.756 .882q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.888q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM27.62 20.169q-.0 .923 .387 1.458q.393 .53 1.22 .53q.84 .0 1.221 -.53q.387 -.535 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" id="mol1atm6" stroke="none"/>
                  
            <path class="atom" d="M17.957 45.482h-.72l-2.62 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.483v-2.768h.578v4.9z" fill="#3050F8" id="mol1atm7" stroke="none"/>
                  
            <path class="atom" d="M5.078 65.891q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM1.215 65.891q-.0 .923 .387 1.459q.393 .529 1.22 .529q.84 .0 1.221 -.529q.387 -.536 .387 -1.459q-.0 -.929 -.387 -1.453q-.381 -.523 -1.209 -.523q-.833 -.0 -1.226 .523q-.393 .524 -.393 1.453z" id="mol1atm9" stroke="none"/>
                  
            <path class="atom" d="M58.902 40.808h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.108 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" fill="#3050F8" id="mol1atm11" stroke="none"/>
                  
            <path class="atom" d="M58.902 65.395h-.721l-2.619 -4.066h-.03q.012 .238 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" fill="#3050F8" id="mol1atm13" stroke="none"/>
                  
            <g class="atom" id="mol1atm17">
                        
                <path d="M98.496 3.078q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM94.633 3.078q-.0 .923 .387 1.459q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.386 -.536 .386 -1.459q.0 -.929 -.386 -1.452q-.381 -.524 -1.209 -.524q-.833 -.0 -1.226 .524q-.393 .523 -.393 1.452z" stroke="none"/>
                        
                <path d="M102.803 5.531h-.62v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.62v4.9z" stroke="none"/>
                      
            </g>
                  
            <g class="atom" id="mol1atm18">
                        
                <path d="M89.042 32.055q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM85.178 32.055q.0 .923 .387 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.535 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.227 .524q-.393 .524 -.393 1.453z" stroke="none"/>
                        
                <path d="M93.348 34.507h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.072h2.512v-2.072h.619v4.899z" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd1" stroke="#3050F8" x1="29.224" x2="29.224" y1="69.742" y2="75.43700000000001"/>
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="32.378" x2="37.405" y1="64.073" y2="61.1725"/>
            <line class="hi" id="mol1bnd6" stroke="#3050F8" x1="19.17" x2="24.197000000000003" y1="41.213" y2="38.3125"/>
            <line class="hi" id="mol1bnd7" stroke="#3050F8" x1="16.016" x2="16.016" y1="46.882" y2="52.577"/>
            <line class="hi" id="mol1bnd8" stroke="#3050F8" x1="26.071" x2="21.0435" y1="64.073" y2="61.1725"/>
            <line class="hi" id="mol1bnd10" stroke="#3050F8" x1="12.863" x2="7.840999999999999" y1="41.211" y2="38.3105"/>
            <line class="hi" id="mol1bnd11" stroke="#3050F8" x1="53.687" x2="48.0595" y1="39.411" y2="41.2215"/>
            <line class="hi" id="mol1bnd12" stroke="#3050F8" x1="59.566" x2="62.734" y1="41.94" y2="46.296"/>
            <line class="hi" id="mol1bnd14" stroke="#3050F8" x1="53.687" x2="48.0595" y1="61.892" y2="60.082"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="58.195" x2="59.941500000000005" y1="34.577" y2="29.2235"/>
            <line class="hi" id="mol1bnd18" stroke="#FF0D0D" x1="92.608" x2="86.967" y1="3.848" y2="5.0395"/>
            <line class="hi" id="mol1bnd19" stroke="#FF0D0D" x1="84.125" x2="80.362" y1="29.099" y2="24.9095"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Taste":"EXTREME BITTER TASTE","Therapeutic Uses":"Bronchodilator Agents; Phosphodiesterase Inhibitors; Vasodilator Agents","Title":"Diprophylline","UNII":"263T0E9RR9","Wikidata":"Q1073333","Wikipedia":"Diprophylline","XLogP":-1.8,"pH":"(1% AQ SOLN) 6.6 TO 7.3"}